# EDGAR Filing Document

**Accession Number:** 0000320351
**File Stem:** 0001752724-25-176803
**Filing Date:** 2025-7
**Character Count:** 44501
**Document Hash:** 22fcbb0964f10f87680991bde506e148
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-25-176803.hdr.sgml**: 20250724

**ACCESSION NUMBER**: 0001752724-25-176803

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250531

**FILED AS OF DATE**: 20250724

**DATE AS OF CHANGE**: 20250724

**PERIOD START**: 20260228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FIDELITY SELECT PORTFOLIOS
- **CENTRAL INDEX KEY:** 0000320351

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 0228

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-03114
- **FILM NUMBER:** 251146387

**BUSINESS ADDRESS:**
- **STREET 1:** 245 SUMMER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-563-7000

**MAIL ADDRESS:**
- **STREET 1:** 245 SUMMER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

## Series and Classes Contracts Data

### Medical Technology and Devices Portfolio (Series ID: S000007473)

| Class ID   | Class Name                               | Ticker Symbol   |
|:---|:---|:---|
| C000020447 | Medical Technology and Devices Portfolio | FSMEX           |

## Nport-Ex

**Quarterly Holdings Report**

**for**

**Fidelity® Select Portfolios®**

**Medical Technology and Devices Portfolio**

**May 31, 2025**

MES-NPRT1-0725

1.802181.121 ---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Common Stocks - 96.3%** | &nbsp;&nbsp;**Common Stocks - 96.3%** | &nbsp;&nbsp;**Common Stocks - 96.3%** |
|  | Shares | Value ($)<br>|
| FRANCE - 0.8%  |  |  |
| Health Care - 0.8% |  |  |
| Health Care Technology - 0.0% |  |  |
| DNA Script SAS (b)(c)(d) | 4668 | 143002 |
| DNA Script SAS (b)(c)(d) | 1220 | 37318 |
|  |  | 180320 |
| Life Sciences Tools & Services - 0.8% |  |  |
| Sartorius Stedim Biotech  | 170000 | 37447141 |
| TOTAL FRANCE |  | 37627461 |
| JAPAN - 0.3%  |  |  |
| Health Care - 0.3% |  |  |
| Health Care Equipment & Supplies - 0.3% |  |  |
| Asahi Intecc Co Ltd  | 1000000 | 15591230 |
| UNITED STATES - 95.2%  |  |  |
| Financials - 0.0% |  |  |
| Financial Services - 0.0% |  |  |
| Saluda Medical Inc warrants 1/20/2027 (b)(c)(d) | 235185 | 265759 |
| Health Care - 95.2% |  |  |
| Biotechnology - 5.0% |  |  |
| Exact Sciences Corp (c) | 2280000 | 128318400 |
| Natera Inc (c) | 220000 | 34700600 |
| Veracyte Inc (c) | 2230000 | 59340300 |
|  |  | 222359300 |
| Health Care Equipment & Supplies - 63.6% |  |  |
| Abbott Laboratories  | 1850000 | 247123000 |
| Alcon AG (United States)  | 1000000 | 85940000 |
| Align Technology Inc (c) | 100000 | 18094000 |
| Boston Scientific Corp (c) | 6080000 | 639980800 |
| Ceribell Inc  | 500000 | 8405000 |
| Cooper Cos Inc/The (c) | 750000 | 51210000 |
| Edwards Lifesciences Corp (c) | 1540000 | 120458800 |
| GE HealthCare Technologies Inc  | 100000 | 7054000 |
| Glaukos Corp (c) | 800000 | 75432000 |
| Globus Medical Inc Class A (c) | 670000 | 39650600 |
| ICU Medical Inc (c) | 280000 | 37760800 |
| IDEXX Laboratories Inc (c) | 60000 | 30801600 |
| Inspire Medical Systems Inc (c)(e) | 535000 | 73937000 |
| Insulet Corp (c) | 670000 | 217770100 |
| Intuitive Surgical Inc (c) | 650000 | 359021000 |
| Kestra Medical Technologies Ltd  | 800000 | 18016000 |
| Masimo Corp (c)(e) | 1320000 | 214500000 |
| Merit Medical Systems Inc (c) | 95000 | 9027850 |
| Outset Medical Inc (c) | 232500 | 4085025 |
| Penumbra Inc (c) | 819752 | 218849191 |
| PROCEPT BioRobotics Corp (c)(e) | 1000000 | 58000000 |
| Stryker Corp  | 825000 | 315678000 |
|  |  | 2850794766 |
| Health Care Providers & Services - 1.7% |  |  |
| Hinge Health Inc (c) | 200000 | 7768000 |
| LifeStance Health Group Inc (c) | 4500000 | 26730000 |
| Privia Health Group Inc (c) | 1800000 | 40968000 |
|  |  | 75466000 |
| Health Care Technology - 6.5% |  |  |
| Doximity Inc Class A (c) | 1000000 | 52090000 |
| Phreesia Inc (c) | 1500000 | 36735000 |
| Prognomiq Inc (b)(c) | 445310 | 111328 |
| Veeva Systems Inc Class A (c) | 670000 | 187399000 |
| Waystar Holding Corp (c) | 370000 | 14792600 |
|  |  | 291127928 |
| Life Sciences Tools & Services - 18.4% |  |  |
| 10X Genomics Inc Class A (c) | 280000 | 2668400 |
| 10X Genomics Inc Class B (c)(f) | 392772 | 3743117 |
| Bruker Corp  | 540000 | 19818000 |
| Danaher Corp  | 2500000 | 474750000 |
| IQVIA Holdings Inc (c) | 400000 | 56132000 |
| Thermo Fisher Scientific Inc  | 550000 | 221551000 |
| West Pharmaceutical Services Inc  | 208000 | 43856800 |
|  |  | 822519317 |
| TOTAL HEALTH CARE |  | 4262267311 |
| TOTAL UNITED STATES |  | 4262533070 |
| <br> **TOTAL COMMON STOCKS**<br> (Cost $2,315,108,087) |  | <br> **4315751761** |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Convertible Corporate Bonds - 0.0%** | &nbsp;&nbsp;**Convertible Corporate Bonds - 0.0%** | &nbsp;&nbsp;**Convertible Corporate Bonds - 0.0%** |
|  | Principal<br> Amount (a)<br>| Value ($)<br>|
| UNITED STATES - 0.0%  |  |  |
| Health Care - 0.0% |  |  |
| Pharmaceuticals - 0.0% |  |  |
| Galvanize Therapeutics 6% 2/28/2027 (b)(d)<br>(Cost $2,433,799)<br>| 2433800 | **2923481** |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Convertible Preferred Stocks - 3.0%** | &nbsp;&nbsp;**Convertible Preferred Stocks - 3.0%** | &nbsp;&nbsp;**Convertible Preferred Stocks - 3.0%** |
|  | Shares | Value ($)<br>|
| CANADA - 0.4%  |  |  |
| Health Care - 0.4% |  |  |
| Health Care Equipment & Supplies - 0.4% |  |  |
| Kardium Inc/CA Series D-6 (b)(c)(d) | 13783189 | 14748012 |
| CHINA - 0.0%  |  |  |
| Health Care - 0.0% |  |  |
| Health Care Providers & Services - 0.0% |  |  |
| dMed Biopharmaceutical Co Ltd Series C (b)(c)(d) | 268502 | 2150700 |
| FRANCE - 0.1%  |  |  |
| Health Care - 0.1% |  |  |
| Health Care Technology - 0.1% |  |  |
| DNA Script SAS Series B (b)(c)(d) | 59 | 2185 |
| DNA Script SAS Series C (b)(c)(d) | 28249 | 6552990 |
| TOTAL FRANCE |  | 6555175 |
| UNITED STATES - 2.5%  |  |  |
| Consumer Discretionary - 0.4% |  |  |
| Textiles, Apparel & Luxury Goods - 0.4% |  |  |
| Freenome Holdings Inc Series C (b)(c)(d) | 2268156 | 10274747 |
| Freenome Holdings Inc Series D (b)(c)(d) | 1325855 | 6509948 |
|  |  | 16784695 |
| Financials - 0.3% |  |  |
| Financial Services - 0.3% |  |  |
| Saluda Medical Inc Series D (b)(c)(d) | 1567904 | 12417800 |
| Health Care - 1.7% |  |  |
| Biotechnology - 0.9% |  |  |
| Asimov Inc Series B (b)(c)(d) | 97985 | 2527033 |
| Caris Life Sciences Inc Series D (b)(c)(d) | 2803935 | 22375402 |
| Element Biosciences Inc Series B (b)(c)(d) | 2385223 | 13452658 |
| ElevateBio LLC Series C (b)(c)(d) | 214700 | 422959 |
|  |  | 38778052 |
| Health Care Providers & Services - 0.3% |  |  |
| Conformal Medical Inc Series C (b)(c)(d) | 2605625 | 10422500 |
| Conformal Medical Inc Series D (b)(c)(d) | 525299 | 2447893 |
|  |  | 12870393 |
| Health Care Technology - 0.5% |  |  |
| Aledade Inc Series B1 (b)(c)(d) | 175232 | 6204966 |
| Aledade Inc Series E1 (b)(c)(d) | 58567 | 2073857 |
| Omada Health Inc Series E (c)(d) | 727646 | 13825274 |
|  |  | 22104097 |
| Pharmaceuticals - 0.0% |  |  |
| Galvanize Therapeutics Series B (b)(c)(d) | 3641139 | 1165164 |
| TOTAL HEALTH CARE |  | 74917706 |
| Materials - 0.1% |  |  |
| Chemicals - 0.1% |  |  |
| Manus Bio Inc Series One-5 (b)(d) | 1716040 | 5216761 |
| TOTAL UNITED STATES |  | 109336962 |
| <br> **TOTAL CONVERTIBLE PREFERRED STOCKS**<br> (Cost $191,870,165) |  | <br> **132790849** |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Preferred Securities - 0.6%** | &nbsp;&nbsp;**Preferred Securities - 0.6%** | &nbsp;&nbsp;**Preferred Securities - 0.6%** |
|  | Principal<br> Amount (a)<br>| Value ($)<br>|
| CANADA - 0.5%  |  |  |
| Health Care - 0.5% |  |  |
| Health Care Equipment & Supplies - 0.5% |  |  |
| Kardium Inc/CA 0% (b)(d)(g) | 19551861 | 20588110 |
| UNITED STATES - 0.1%  |  |  |
| Health Care - 0.1% |  |  |
| Health Care Technology - 0.1% |  |  |
| HeartFlow Inc 0% (b)(d)(g) | 6955700 | 7219321 |
| <br> **TOTAL PREFERRED SECURITIES**<br> (Cost $26,507,561) |  | <br> **27807431** |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Money Market Funds - 0.8%** | &nbsp;&nbsp;**Money Market Funds - 0.8%** | &nbsp;&nbsp;**Money Market Funds - 0.8%** | &nbsp;&nbsp;**Money Market Funds - 0.8%** |
|  | Yield (%) | Shares | Value ($)<br>|
| Fidelity Cash Central Fund (h) | 4.32 | 7355291 | 7356762 |
| Fidelity Securities Lending Cash Central Fund (h)(i) | 4.32 | 28283487 | 28286315 |
| <br> **TOTAL MONEY MARKET FUNDS**<br> (Cost $35,643,077) |  |  | **35643077** |

---

---

| | |
|:---|:---|
| <br> **TOTAL INVESTMENT IN SECURITIES - 100.7%**<br> (Cost $2,571,562,689)<br>| <br>**4514916599** |
| **NET OTHER ASSETS (LIABILITIES) - (0.7)%**  | **(32779587)** |
| **NET ASSETS - 100.0%** | **4482137012** |

---

**Legend**

(a) Amount is stated in United States dollars unless otherwise noted.

(b) Level 3 security

(c) Non-income producing

(d) Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $163,967,840 or 3.7% of net assets.

(e) Security or a portion of the security is on loan at period end.

(f) Security exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $3,743,117 or 0.1% of net assets.

(g) Security is perpetual in nature with no stated maturity date.

(h) Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.

(i) Investment made with cash collateral received from securities on loan.

---

| | | |
|:---|:---|:---|
| Additional information on each restricted holding is as follows: | Additional information on each restricted holding is as follows: | Additional information on each restricted holding is as follows: |
| Security | Acquisition Date | Acquisition Cost ($)<br>|
| Aledade Inc Series B1 | 5/07/21 | 6709756 |
| Aledade Inc Series E1 | 5/20/22 | 2917480 |
| Asimov Inc Series B | 10/29/21 | 9081318 |
| Caris Life Sciences Inc Series D | 5/11/21 | 22711874 |
| Conformal Medical Inc Series C | 7/24/20 | 9554996 |
| Conformal Medical Inc Series D | 5/26/23 | 2668340 |
| dMed Biopharmaceutical Co Ltd Series C | 12/01/20 | 3813574 |
| DNA Script SAS | 12/17/21 | 3737869 |
| DNA Script SAS | 12/17/21 | 976907 |
| DNA Script SAS Series B | 12/17/21 | 47244 |
| DNA Script SAS Series C | 10/01/21 | 24572393 |
| Element Biosciences Inc Series B | 12/13/19 | 12500000 |
| ElevateBio LLC Series C | 3/09/21 | 900667 |
| Freenome Holdings Inc Series C | 8/14/20 | 14999996 |
| Freenome Holdings Inc Series D | 11/22/21 | 9999996 |
| Galvanize Therapeutics 6% 2/28/2027 | 2/28/24 | 2433800 |
| Galvanize Therapeutics Series B | 3/29/22 | 6303849 |
| HeartFlow Inc 0% | 3/26/25 | 6955700 |
| Kardium Inc/CA 0% | 12/30/20 | 19551861 |
| Kardium Inc/CA Series D-6 | 12/30/20 | 14001515 |
| Manus Bio Inc Series One-5 | 11/13/20 | 18000001 |
| Omada Health Inc Series E | 12/22/21 | 13087156 |
| Saluda Medical Inc Series D | 1/20/22 | 20000011 |
| Saluda Medical Inc warrants 1/20/2027 | 1/20/22 | 0 |

---

**Affiliated Central Funds**

Fiscal year to date information regarding the Fund's investments in Fidelity Central Funds, including the ownership percentage, is presented below.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Affiliate  | Value,<br> beginning<br> of period ($) | Purchases ($) | Sales<br> Proceeds ($) | Dividend<br> Income ($) | Realized<br> Gain (loss) ($) | Change in<br> Unrealized<br> appreciation<br> (depreciation) ($) | Value,<br> end<br> of period ($) | <br>Shares,<br> end<br> of period  | % ownership,<br> end<br> of period |
| Fidelity Cash Central Fund | 26564630 | 302827166 | 322035034 | 697688 | - | - | 7356762 | 7355291 | 0.0% |
| Fidelity Securities Lending Cash Central Fund | 25853699 | 137318256 | 134885640 | 24811 | - | - | 28286315 | 28283487 | 0.1% |
| Total | 52418329 | 440145422 | 456920674 | 722499 | - | - | 35643077 |  |  |

---

Amounts in the dividend income column in the above table include any capital gain distributions from underlying funds.

Amounts in the dividend income column for Fidelity Securities Lending Cash Central Fund represents the income earned on investing cash collateral, less rebates paid to borrowers and any lending agent fees associated with the loan, plus any premium income received for lending certain types of securities.

**Other Affiliated Issuers**

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities. Fiscal year to date transactions with companies which are or were affiliates are presented in the table below. Certain corporate actions, such as mergers, are excluded from the amounts in this table if applicable. A dash in the Value end of period ($) and Shares end of period columns means either the issuer is no longer held at period end, or the issuer is held at period end but is no longer an affiliate.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Affiliate  | Value,<br> beginning<br> of period ($) | Purchases ($) | Sales<br> Proceeds ($) | Dividend<br> Income ($) | Realized<br> Gain (loss) ($) | Change in<br> Unrealized<br> appreciation<br> (depreciation) ($) | Value,<br> end<br> of period ($) | <br>Shares,<br> end<br> of period  |
| Outset Medical Inc | 2507222 | 28613 | - | - | (401) | 1549591 | - | - |
| Total | 2507222 | 28613 | - | - | (401) | 1549591 | - |  |

---

**Investment Valuation**

Investments are valued as of 4:00 p.m. Eastern time on the last calendar day of the period. Securities transactions are accounted for as of trade date. The Board of Trustees (the Board) has designated the Fund's investment adviser as the valuation designee responsible for the fair valuation function and performing fair value determinations as needed. The investment adviser has established a Fair Value Committee (the Committee) to carry out the day-to-day fair valuation responsibilities and has adopted policies and procedures to govern the fair valuation process and the activities of the Committee. In accordance with these fair valuation policies and procedures, which have been approved by the Board, the Fund attempts to obtain prices from one or more third party pricing services or brokers to value its investments. When current market prices, quotations or currency exchange rates are not readily available or reliable, investments will be fair valued in good faith by the Committee, in accordance with the policies and procedures. Factors used in determining fair value vary by investment type and may include market or investment specific events, transaction data, estimated cash flows, and market observations of comparable investments. The frequency that the fair valuation procedures are used cannot be predicted and they may be utilized to a significant extent. The Committee manages the Fund's fair valuation practices and maintains the fair valuation policies and procedures. The Fund's investment adviser reports to the Board information regarding the fair valuation process and related material matters.

The inputs to valuation techniques used to value investments are categorized into a disclosure hierarchy consisting of three levels as shown below:

Level 1 - Unadjusted quoted prices in active markets for identical investments

Level 2 - other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, etc.)

Level 3 - unobservable inputs (including the Fund's own assumptions based on the best information available)

Valuation techniques used to value investments by major category are as follows:

Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party pricing service on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the last quoted bid price or may be valued using the last available price and are generally categorized as Level 2 in the hierarchy. For any foreign equity securities, when market or security specific events arise, comparisons to the valuation of American Depositary Receipts (ADRs), futures contracts, Exchange-Traded Funds (ETFs) and certain indexes as well as quoted prices for similar securities may be used and would be categorized as Level 2 in the hierarchy. For equity securities, including restricted securities, where observable inputs are limited, assumptions about market activity and risk are used and these securities may be categorized as Level 3 in the hierarchy.

Securities, including private placements or other restricted securities, for which observable inputs are not available are valued using alternate valuation approaches, including the market approach, the income approach and cost approach, and are categorized as Level 3 in the hierarchy. The market approach considers factors including the price of recent investments in the same or a similar security or financial metrics of comparable securities. The income approach considers factors including expected future cash flows, security specific risks and corresponding discount rates. The cost approach considers factors including the value of the security's underlying assets and liabilities.

Debt securities, including restricted securities, are valued based on evaluated prices received from third party pricing services or from brokers who make markets in such securities. Convertible Corporate Bonds and Preferred Securities are valued by pricing services who utilize matrix pricing which considers yield or price of bonds of comparable quality, coupon, maturity and type or by broker-supplied prices. When independent prices are unavailable or unreliable, debt securities may be valued utilizing pricing methodologies which consider similar factors that would be used by third party pricing services. Debt securities are generally categorized as Level 2 in the hierarchy but may be Level 3 depending on the circumstances.

Investments in any open-end mutual funds are valued at their closing net asset value (NAV) each business day and are categorized as Level 1 in the hierarchy.

Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy.

For additional information on the Fund's significant accounting policies, please refer to the Fund's most recent semiannual or annual shareholder report.

*The fund's schedule of investments as of the date on the cover of this report has not been audited. This report is provided for the general information of the fund's shareholders. For more information regarding the fund and its holdings, please see the fund's most recent prospectus and annual report.*

*Third party trademarks and service marks are the property of their respective owners. All other trademarks and service marks are the property of FMR LLC or an affiliate.*

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Fidelity Select Portfolios

- **b. Investment Company Act file number:** 811-03114

- **c. CIK number of Registrant:** 0000320351

- **d. LEI of Registrant:** Z57125JG1LHEQKDYS630

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 245 Summer Street

  - **City:** Boston

  - **State:** MA

  - **Foreign country:** US

  - **Zip / Postal Code:** 02210

  - **Telephone number:** 1-800-FIDELITY

**Item A.2. Information about the Series.**

- **a. Name of Series:** Select Medical Technology and Devices Portfolio

- **b. EDGAR series identifier (if any):** S000007473

- **c. LEI of Series:** Y7COW23MC3TDILXWQ777

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-02-28

- **b. Date as of which information is reported:** 2025-05-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $4516069734.94

**Total Liabilities:** $32045743.80

**Net Assets:** $4484023991.14

**Cash Not Reported:** $243632.13

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000020447 | -5.82%               | -0.77%               | 1.35%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $27571319.64             | $-317024003.09                             |
| Month 2  | $58925464.32             | $-97648893.35                              |
| Month 3  | $54941470.25             | $7319688.67                                |

### Schedule of Portfolio Investments

| Name                            | Title                                         | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| CERIBELL INC                    | CERIBELL INC                                  | CUSIP: 15678C102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    500000 | NS      | $8405000.00   | 0.19%             |  |  |  | No            |                  1 | On Loan: No      |
| THERMO FISHER SCIENTIFIC INC    | THERMO FISHER SCIENTIFIC INC                  | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |    550000 | NS      | $221551000.00 | 4.94%             |  |  |  | No            |                  1 | On Loan: No      |
| PENUMBRA INC                    | PENUMBRA INC                                  | CUSIP: 70975L107<br>LEI: 549300RGE06P3ECANU72 | Long             | EC               | CORP              | US        |    819752 | NS      | $218849191.44 | 4.88%             |  |  |  | No            |                  1 | On Loan: No      |
| IQVIA HOLDINGS INC              | IQVIA HOLDINGS INC                            | CUSIP: 46266C105<br>LEI: 549300W3R20NM4KQPH86 | Long             | EC               | CORP              | US        |    400000 | NS      | $56132000.00  | 1.25%             |  |  |  | No            |                  1 | On Loan: No      |
| ALIGN TECHNOLOGY INC            | ALIGN TECHNOLOGY INC                          | CUSIP: 016255101<br>LEI: 549300N5YSE0U3LCP840 | Long             | EC               | CORP              | US        |    100000 | NS      | $18094000.00  | 0.40%             |  |  |  | No            |                  1 | On Loan: No      |
| PRIVIA HEALTH GROUP INC         | PRIVIA HEALTH GROUP INC                       | CUSIP: 74276R102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1850000 | NS      | $42106000.00  | 0.94%             |  |  |  | No            |                  1 | On Loan: No      |
| STRYKER CORP                    | STRYKER CORP                                  | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |    825000 | NS      | $315678000.00 | 7.04%             |  |  |  | No            |                  1 | On Loan: No      |
| MANUS BIO INC                   | MANUS BIO INC SER ONE-5 PC PP                 | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1716040 | NS      | $5216761.60   | 0.12%             |  |  |  | Yes           |                  3 | On Loan: No      |
| SALUDA MEDICAL INC              | SALUDA MEDICAL INC WT PP                      | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |    235185 | NS      | $265759.05    | 0.01%             |  |  |  | Yes           |                  3 | On Loan: No      |
| PHREESIA INC                    | PHREESIA INC                                  | CUSIP: 71944F106<br>LEI: 5493000HHF8NU4QOCG53 | Long             | EC               | CORP              | US        |   1500000 | NS      | $36735000.00  | 0.82%             |  |  |  | No            |                  1 | On Loan: No      |
| DNA SCRIPT SAS                  | DNA SCRIPT SAS(SEED) PP                       | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | FR        |      4668 | NS      | $143001.57    | 0.00%             |  |  |  | Yes           |                  3 | On Loan: No      |
| KESTRA MEDICAL TECHNOLOGIES INC | KESTRA MEDICAL TECHNOLOGIES INC               | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |    800000 | NS      | $18016000.00  | 0.40%             |  |  |  | No            |                  1 | On Loan: No      |
| BRUKER CORP                     | BRUKER CORP                                   | CUSIP: 116794108<br>LEI: LEBZ6VLQ6I8XB1NHVY15 | Long             | EC               | CORP              | US        |    540000 | NS      | $19818000.00  | 0.44%             |  |  |  | No            |                  1 | On Loan: No      |
| KARDIUM INC/CA                  | KARDIUM INC CONV 0% PERP PP                   | CUSIP: N/A<br>LEI: 549300YO4UGSBRMWPN13       | Long             | EP               | CORP              | CA        |  19551861 | PA      | $20588109.63  | 0.46%             |  |  |  | Yes           |                  3 | On Loan: No      |
| ASIMOV INC                      | ASIMOV INC SER B PC PP                        | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |     97985 | NS      | $2527033.15   | 0.06%             |  |  |  | Yes           |                  3 | On Loan: No      |
| GALVANIZE THERAPEUTICS          | GALVANIZE THERAPEUTICS CONV 6% 02/28/2027 P/P | CUSIP: N/A<br>LEI: N/A                        | Long             | DBT              | CORP              | US        |   2433800 | PA      | $2923480.56   | 0.07%             | 2027-02-28      | Fixed         | 0.06%                 | Yes           |                  3 | On Loan: No      |
| COOPER COMPANIES INC            | COOPER COMPANIES INC                          | CUSIP: 216648501<br>LEI: QJKMVPIGLH7530PCUE20 | Long             | EC               | CORP              | US        |    750000 | NS      | $51210000.00  | 1.14%             |  |  |  | No            |                  1 | On Loan: No      |
| CARIS LIFE SCIENCES INC         | CARIS LIFE SCIENCES INC SER D PC PP           | CUSIP: N/A<br>LEI: 549300LX5LO78M5VPY43       | Long             | EP               | CORP              | US        |   2803935 | NS      | $22375401.30  | 0.50%             |  |  |  | Yes           |                  3 | On Loan: No      |
| LIFESTANCE HEALTH GROUP INC     | LIFESTANCE HEALTH GROUP INC                   | CUSIP: 53228F101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   4500000 | NS      | $26730000.00  | 0.60%             |  |  |  | No            |                  1 | On Loan: No      |
| 10X GENOMICS INC                | 10X GENOMICS INC                              | CUSIP: 88025U109<br>LEI: 5493003Z6741WNLG7H43 | Long             | EC               | CORP              | US        |    200000 | NS      | $1906000.00   | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| DMED BIOPHARMACEUTICAL CO LTD   | DMED BIOPHARMACEUTICAL CO LTD SER C PC PP     | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | CN        |    268502 | NS      | $2150701.02   | 0.05%             |  |  |  | Yes           |                  3 | On Loan: No      |
| SALUDA MEDICAL INC              | SALUDA MEDICAL INC SER D PC PP                | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1567904 | NS      | $12417799.68  | 0.28%             |  |  |  | Yes           |                  3 | On Loan: No      |
| ALEDADE INC                     | ALEDADE INC SER B1 PC PP                      | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    175232 | NS      | $6204965.12   | 0.14%             |  |  |  | Yes           |                  3 | On Loan: No      |
| FREENOME INC                    | FREENOME HOLDINGS INC SER C PC PP             | CUSIP: N/A<br>LEI: 254900QDTSQ6S0QOCS43       | Long             | EP               | CORP              | US        |   2268156 | NS      | $10274746.68  | 0.23%             |  |  |  | Yes           |                  3 | On Loan: No      |
| DNA SCRIPT SAS                  | DNA SCRIPT SAS PP                             | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | FR        |      1220 | NS      | $37318.61     | 0.00%             |  |  |  | Yes           |                  3 | On Loan: No      |
| DNA SCRIPT SAS                  | DNA SCRIPT SAS SER B PC PP                    | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | FR        |        59 | NS      | $2185.26      | 0.00%             |  |  |  | Yes           |                  3 | On Loan: No      |
| GALVANIZE THERAPEUTICS          | GALVANIZE THERAPEUTICS SER B PC PERP PP       | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   3641139 | NS      | $1165164.48   | 0.03%             |  |  |  | Yes           |                  3 | On Loan: No      |
| KARDIUM INC/CA                  | KARDIUM INC SRE D-6 PC PP                     | CUSIP: N/A<br>LEI: 549300YO4UGSBRMWPN13       | Long             | EP               | CORP              | CA        |  13783189 | NS      | $14748012.23  | 0.33%             |  |  |  | Yes           |                  3 | On Loan: No      |
| PROCEPT BIOROBOTICS CORP        | PROCEPT BIOROBOTICS CORP                      | CUSIP: 74276L105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1000000 | NS      | $58000000.00  | 1.29%             |  |  |  | No            |                  1 | On Loan: —       |
| WAYSTAR HOLDING CORP            | WAYSTAR HOLDING CORP                          | CUSIP: 946784105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    370000 | NS      | $14792600.00  | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| GLOBUS MEDICAL INC              | GLOBUS MEDICAL INC                            | CUSIP: 379577208<br>LEI: 5299003M2P4CIK0RF205 | Long             | EC               | CORP              | US        |    670000 | NS      | $39650600.00  | 0.88%             |  |  |  | No            |                  1 | On Loan: No      |
| VERACYTE INC                    | VERACYTE INC                                  | CUSIP: 92337F107<br>LEI: 529900ESWZRHXOW27Z37 | Long             | EC               | CORP              | US        |   2230000 | NS      | $59340300.00  | 1.32%             |  |  |  | No            |                  1 | On Loan: No      |
| HEARTFLOW INC                   | HEARTFLOW INC CONV 0% PERP P/P                | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   6955700 | PA      | $7219321.03   | 0.16%             |  |  |  | Yes           |                  3 | On Loan: No      |
| PROGNOMIQ INC                   | PROGNOMIQ INC                                 | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |    445310 | NS      | $111327.50    | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| OUTSET MEDICAL INC              | OUTSET MEDICAL INC                            | CUSIP: 690145206<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    232500 | NS      | $4085025.00   | 0.09%             |  |  |  | No            |                  1 | On Loan: No      |
| GE HEALTHCARE TECHNOLOGIES INC  | GE HEALTHCARE TECHNOLOGIES INC WI             | CUSIP: 36266G107<br>LEI: 549300OI9J7XOWZMUN85 | Long             | EC               | CORP              | US        |    100000 | NS      | $7054000.00   | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| BOSTON SCIENTIFIC CORP          | BOSTON SCIENTIFIC CORP                        | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |   6080000 | NS      | $639980800.00 | 14.27%            |  |  |  | No            |                  1 | On Loan: No      |
| ALEDADE INC                     | ALEDADE INC SER E1 PC PP                      | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |     58567 | NS      | $2073857.47   | 0.05%             |  |  |  | Yes           |                  3 | On Loan: No      |
| ABBOTT LABORATORIES             | ABBOTT LABORATORIES                           | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |   1850000 | NS      | $247123000.00 | 5.51%             |  |  |  | No            |                  1 | On Loan: No      |
| FREENOME INC                    | FREENOME HOLDINGS INC SER D PC PP             | CUSIP: N/A<br>LEI: 254900QDTSQ6S0QOCS43       | Long             | EP               | CORP              | US        |   1325855 | NS      | $6509948.05   | 0.15%             |  |  |  | Yes           |                  3 | On Loan: No      |
| 10X GENOMICS INC                | 10X GENOMICS INC CL B 144A                    | CUSIP: N/A<br>LEI: 5493003Z6741WNLG7H43       | Long             | EC               | CORP              | US        |    392772 | NS      | $3743117.16   | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| ELEMENT BIOSCIENCES INC         | ELEMENT BIOSCIENCES INC SER B PC PP           | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   2385223 | NS      | $13452657.72  | 0.30%             |  |  |  | Yes           |                  3 | On Loan: No      |
| INTUITIVE SURGICAL INC          | INTUITIVE SURGICAL INC                        | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |    650000 | NS      | $359021000.00 | 8.01%             |  |  |  | No            |                  1 | On Loan: No      |
| CONFORMAL MEDICAL INC           | CONFORMAL MEDICAL INC SER C PC PP             | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   2605625 | NS      | $10422500.00  | 0.23%             |  |  |  | Yes           |                  3 | On Loan: No      |
| WEST PHARMACEUTICAL SVCS INC    | WEST PHARMACEUTICAL SVCS INC                  | CUSIP: 955306105<br>LEI: 5493007NKRGM1RJQ1P16 | Long             | EC               | CORP              | US        |    208000 | NS      | $43856800.00  | 0.98%             |  |  |  | No            |                  1 | On Loan: No      |
| Fidelity Revere Street Trust    | Fidelity Cash Central Fund                    | CUSIP: 31635A105<br>LEI: 549300BDV45LJNXBZC55 | Long             | STIV             | RF                | US        |   7355291 | NS      | $7356762.20   | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| EDWARDS LIFESCIENCES CORP       | EDWARDS LIFESCIENCES CORP                     | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |   1540000 | NS      | $120458800.00 | 2.69%             |  |  |  | No            |                  1 | On Loan: No      |
| SARTORIUS STEDIM BIOTECH        | SARTORIUS STEDIM BIOTECH                      | CUSIP: N/A<br>LEI: 52990006IVXY7GCSSR39       | Long             | EC               | CORP              | FR        |    170000 | NS      | $37447140.97  | 0.84%             |  |  |  | No            |                  1 | On Loan: No      |
| DANAHER CORP                    | DANAHER CORP                                  | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |   2500000 | NS      | $474750000.00 | 10.59%            |  |  |  | No            |                  1 | On Loan: No      |
| GLAUKOS CORP                    | GLAUKOS CORP                                  | CUSIP: 377322102<br>LEI: 5299004JA1LHE21M6T14 | Long             | EC               | CORP              | US        |    800000 | NS      | $75432000.00  | 1.68%             |  |  |  | No            |                  1 | On Loan: No      |
| NATERA INC                      | NATERA INC                                    | CUSIP: 632307104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    220000 | NS      | $34700600.00  | 0.77%             |  |  |  | No            |                  1 | On Loan: No      |
| EXACT SCIENCES CORP             | EXACT SCIENCES CORP                           | CUSIP: 30063P105<br>LEI: 549300VM3X1FYD4N9Z14 | Long             | EC               | CORP              | US        |   2280000 | NS      | $128318400.00 | 2.86%             |  |  |  | No            |                  1 | On Loan: No      |
| DOXIMITY INC                    | DOXIMITY INC                                  | CUSIP: 26622P107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1000000 | NS      | $52090000.00  | 1.16%             |  |  |  | No            |                  1 | On Loan: No      |
| IDEXX LABORATORIES INC          | IDEXX LABS INC                                | CUSIP: 45168D104<br>LEI: OGMTXK0LUU1HKV2P0J84 | Long             | EC               | CORP              | US        |     60000 | NS      | $30801600.00  | 0.69%             |  |  |  | No            |                  1 | On Loan: No      |
| Fidelity Revere Street Trust    | Fidelity Securities Lending Cash Central Fund | CUSIP: 31635A303<br>LEI: 549300BDV45LJNXBZC55 | Long             | STIV             | RF                | US        |  29384177 | NS      | $29387115.07  | 0.66%             |  |  |  | No            |                  1 | On Loan: No      |
| ASAHI INTECC CO LTD             | ASAHI INTECC CO LTD                           | CUSIP: N/A<br>LEI: 353800J3AV2SCNIO8L39       | Long             | EC               | CORP              | JP        |   1000000 | NS      | $15591229.72  | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| VEEVA SYS INC                   | VEEVA SYS INC CL A                            | CUSIP: 922475108<br>LEI: 549300YZEXPDB92M2F02 | Long             | EC               | CORP              | US        |    650000 | NS      | $181805000.00 | 4.05%             |  |  |  | No            |                  1 | On Loan: No      |
| INSPIRE MEDICAL SYSTEMS INC     | INSPIRE MEDICAL SYSTEMS INC                   | CUSIP: 457730109<br>LEI: 549300XQQCQ7HCJKTW25 | Long             | EC               | CORP              | US        |    535000 | NS      | $73937000.00  | 1.65%             |  |  |  | No            |                  1 | On Loan: —       |
| CONFORMAL MEDICAL INC           | CONFORMAL MEDICAL INC SER D PC PP             | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    525299 | NS      | $2447893.34   | 0.05%             |  |  |  | Yes           |                  3 | On Loan: No      |
| ICU MEDICAL INC                 | ICU MEDICAL INC                               | CUSIP: 44930G107<br>LEI: 5493003NRW7LS2QZRH60 | Long             | EC               | CORP              | US        |    280000 | NS      | $37760800.00  | 0.84%             |  |  |  | No            |                  1 | On Loan: No      |
| ALCON INC                       | ALCON INC                                     | CUSIP: N/A<br>LEI: 549300LDT5AP8S0NBM78       | Long             | EC               | CORP              | CH        |   1000000 | NS      | $85940000.00  | 1.92%             |  |  |  | No            |                  1 | On Loan: No      |
| INSULET CORP                    | INSULET CORP                                  | CUSIP: 45784P101<br>LEI: 549300TZTYD2PYN92D43 | Long             | EC               | CORP              | US        |    670000 | NS      | $217770100.00 | 4.86%             |  |  |  | No            |                  1 | On Loan: No      |
| OMADA HEALTH INC                | OMADA HEALTH INC SER E PC PP                  | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    727646 | NS      | $13825274.00  | 0.31%             |  |  |  | Yes           |                  2 | On Loan: No      |
| MERIT MEDICAL SYSTEMS INC       | MERIT MEDICAL SYSTEMS INC                     | CUSIP: 589889104<br>LEI: 549300OYTY138SP2CE83 | Long             | EC               | CORP              | US        |     95000 | NS      | $9027850.00   | 0.20%             |  |  |  | No            |                  1 | On Loan: No      |
| ELEVATEBIO, LLC                 | ELEVATEBIO LLC SER C PC PP                    | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    214700 | NS      | $422959.00    | 0.01%             |  |  |  | Yes           |                  3 | On Loan: No      |
| DNA SCRIPT SAS                  | DNA SCRIPT SAS SER C PC PP                    | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | FR        |     28249 | NS      | $6552989.31   | 0.15%             |  |  |  | Yes           |                  3 | On Loan: No      |
| MASIMO CORP                     | MASIMO CORP                                   | CUSIP: 574795100<br>LEI: 549300Q4A8JK0PIYCU29 | Long             | EC               | CORP              | US        |   1345434 | NS      | $218633025.00 | 4.88%             |  |  |  | No            |                  1 | On Loan: —       |
| HINGE HEALTH INC                | HINGE HEALTH INC                              | CUSIP: 433313103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    200000 | NS      | $7768000.00   | 0.17%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-06-30

**Name of Applicant:** Stacie M. Smith

**Signature:** Stacie M. Smith

**Name of Signer:** Stacie M. Smith

**Title:** President and Treasurer